David J Lefer Selected Research

Sodium Nitrite

1/2016	Nitrite Therapy Ameliorates Myocardial Dysfunction via H2S and Nuclear Factor-Erythroid 2-Related Factor 2 (Nrf2)-Dependent Signaling in Chronic Heart Failure.
7/2015	Sustained release nitrite therapy results in myocardial protection in a porcine model of metabolic syndrome with peripheral vascular disease.
7/2015	Therapeutic potential of sustained-release sodium nitrite for critical limb ischemia in the setting of metabolic syndrome.
4/2014	Nitrite therapy improves left ventricular function during heart failure via restoration of nitric oxide-mediated cytoprotective signaling.
7/2012	Single-dose pharmacokinetics of different oral sodium nitrite formulations in diabetes patients.
5/2008	Chronic sodium nitrite therapy augments ischemia-induced angiogenesis and arteriogenesis.
5/2005	Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David J Lefer Research Topics

Disease

36	Myocardial Ischemia (Ischemic Heart Diseases) 10/2020 - 06/2002
34	Reperfusion Injury 10/2020 - 09/2002
25	Ischemia 07/2020 - 09/2002
23	Heart Failure 07/2022 - 04/2003
23	Myocardial Infarction 01/2019 - 09/2002
16	Cardiovascular Diseases (Cardiovascular Disease) 07/2022 - 04/2005
14	Infarction (Infarctions) 07/2020 - 04/2003
6	Hypertension (High Blood Pressure) 02/2021 - 07/2009
6	Chronic Limb-Threatening Ischemia 01/2017 - 09/2007
6	Necrosis 08/2015 - 09/2002
6	Inflammation (Inflammations) 06/2011 - 04/2004
4	Obesity 03/2021 - 10/2007
4	Fibrosis (Cirrhosis) 11/2018 - 01/2016
4	Myocardial Reperfusion Injury 01/2016 - 01/2003
3	Hypertrophy 01/2022 - 04/2014
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 03/2021 - 07/2015
3	Pathologic Processes 01/2016 - 01/2013
3	Atherosclerosis 01/2016 - 06/2005
3	Hypoxia (Hypoxemia) 12/2009 - 05/2005
2	Coronary Artery Disease (Coronary Atherosclerosis) 01/2020 - 05/2005
2	Ventricular Remodeling 01/2020 - 09/2013
2	Diabetic Cardiomyopathies 12/2019 - 01/2019
2	Cardiomegaly (Heart Hypertrophy) 01/2018 - 12/2006
2	Pulmonary Edema 01/2016 - 12/2006
2	Heart Diseases (Heart Disease) 01/2016 - 05/2014
2	Peripheral Vascular Diseases (Peripheral Vascular Disease) 07/2015 - 07/2015
2	Insulin Resistance 02/2013 - 07/2009
2	Hyperlipidemias (Hyperlipidemia) 02/2013 - 09/2006
2	Shock 05/2005 - 01/2004
2	Hypercholesterolemia 04/2005 - 04/2004
1	Pulmonary Hypertension 01/2022
1	Type 2 Diabetes Mellitus (MODY) 12/2019

Drug/Important Bio-Agent (IBA)

22	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 03/2021 - 09/2007
19	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2016 - 09/2002
17	NitritesIBA 01/2016 - 05/2005
12	Nitric Oxide Synthase (NO Synthase)IBA 07/2015 - 01/2003
7	EnzymesIBA 07/2022 - 01/2003
7	Sodium NitriteIBA 01/2016 - 05/2005
6	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 03/2013 - 06/2002
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 09/2006 - 09/2002
4	Peptides (Polypeptides)IBA 07/2020 - 12/2007
4	Troponin IIBA 01/2016 - 08/2009
3	Proteins (Proteins, Gene)FDA Link 07/2022 - 02/2007
3	KATP ChannelsIBA 01/2020 - 03/2008
3	Neprilysin (Neutral Endopeptidase)IBA 11/2018 - 10/2017
3	salicylhydroxamic acid (SHAM)IBA 10/2017 - 01/2006
3	NitratesIBA 01/2016 - 11/2007
3	CytokinesIBA 08/2015 - 09/2006
3	LipidsIBA 02/2013 - 05/2005
3	ChloridesIBA 10/2010 - 10/2007
3	Simvastatin (Zocor)FDA LinkGeneric 12/2006 - 06/2005
3	Coenzyme A (CoA)IBA 09/2006 - 09/2002
3	CholesterolIBA 09/2006 - 05/2005
2	LyasesIBA 10/2020 - 07/2010
2	humaninIBA 07/2020 - 10/2010
2	Choline (Choline Chloride)IBA 01/2020 - 01/2016
2	trimethyloxamine (trimethylamine N-oxide)IBA 01/2020 - 01/2016
2	CollagenIBA 01/2019 - 01/2018
2	ProdrugsIBA 01/2019 - 01/2017
2	Brain Natriuretic Peptide (Natrecor)FDA Link 11/2018 - 01/2016
2	Vasodilator Agents (Vasodilators)IBA 11/2018 - 03/2016
2	Angiotensin Receptors (Angiotensin II Receptor)IBA 11/2018 - 01/2018
2	Adenosine Triphosphate (ATP)IBA 01/2018 - 03/2008
2	Biological ProductsIBA 01/2017 - 10/2007
2	Nebivolol FDA Link 03/2016 - 12/2011
2	Apolipoproteins E (ApoE)IBA 01/2016 - 09/2006
2	Delayed-Action PreparationsIBA 07/2015 - 07/2015
2	Pharmaceutical PreparationsIBA 02/2015 - 02/2009
2	Drinking WaterIBA 11/2013 - 11/2007
2	Metformin (Glucophage)FDA LinkGeneric 02/2009 - 03/2008
2	Hypoglycemic Agents (Hypoglycemics)IBA 02/2009 - 03/2008
2	AMP-Activated Protein KinasesIBA 02/2009 - 03/2008
2	Sulfonylurea ReceptorsIBA 02/2009 - 03/2008
2	AntioxidantsIBA 08/2008 - 01/2003
2	N,N,N-trimethylsphingosineIBA 03/2008 - 10/2007
2	SphingolipidsIBA 03/2008 - 10/2007
2	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 09/2007 - 01/2007
2	Sildenafil Citrate (Viagra)FDA Link 09/2007 - 01/2007
2	Fas Ligand Protein (Fas Ligand)IBA 09/2006 - 04/2003
2	Superoxides (Superoxide)IBA 04/2006 - 12/2005
1	ThiophenesIBA 07/2022
1	Carboxylic AcidsIBA 07/2022
1	Branched-Chain Amino AcidsIBA 07/2022
1	Nicotine FDA Link 01/2022
1	Glucose (Dextrose)FDA LinkGeneric 03/2021
1	Acetates (Acetic Acid Esters)FDA Link 02/2021
1	SaltsIBA 02/2021
1	CystathionineIBA 10/2020
1	Gly(14)-HumaninIBA 07/2020
1	mitochondrial K(ATP) channelIBA 01/2020
1	Potassium Channels (Potassium Channel)IBA 01/2020
1	Phosphatidylcholines (Phosphatidylcholine)IBA 01/2020
1	methyl 6,7- dimethoxy- 4- ethyl- beta- carboline- 3- carboxylateIBA 12/2019
1	chenodeoxycholate sulfate conjugate (CDCS)IBA 01/2019
1	Cystathionine beta-Synthase (Serine Sulfhydrase)IBA 01/2019

Therapy/Procedure

34	Therapeutics 03/2021 - 09/2002
4	Denervation 10/2021 - 01/2016
3	Ligation 01/2016 - 12/2006
2	Transplantation 02/2010 - 05/2005
1	Cell Transplantation 01/2019